摘要
哮喘是一种以气道慢性炎症为特征的异质性疾病,全世界大约有3.34亿哮喘患者,其中约3%~10%的患者为重度哮喘。重度哮喘患者生活质量严重降低、肺功能明显受损,给个人、家庭和社会带来沉重的经济负担。近年来,以胸腺基质淋巴细胞生成素(TSLP)为治疗靶点的生物制剂在重度哮喘的治疗中取得了一定进展。Tezepelumab是第一个用于治疗哮喘的抗TSLP单克隆抗体,也是目前最新批准用于治疗重度哮喘的靶向药物。国外已有大量研究证实Tezepelumab可以减少哮喘急性加重次数、减轻哮喘症状、改善肺功能和提高患者生活质量。目前,国内尚无Tezepelumab治疗重度哮喘相关的研究报道。因此,本文对Tezepelumab治疗重度哮喘的研究现状进行综述,以期为进一步的临床实践提供科学依据。
Asthma is a heterogeneous disease characterized by chronic airway inflammation.There are about 334 million patients with asthma worldwide,and about 3%to 10%of the patients with asthma are severe asthma.The quality of life of patients with severe asthma is severely reduced and lung function is significantly impaired,which brings a heavy economic burden to individuals,families and society.In recent years,biological agents targeting thymic stromal lymphopoietin(TSLP)have made some progress in the treatment of severe asthma.Tezepelumab is the first monoclonal antibody against TSLP for the treatment of asthma and the latest targeted drug currently approved for the treatment of severe asthma.A large number of studies abroad have confirmed that tezepelumab can reduce the annual exacerbation rate of asthma,improve lung function,control asthma symptoms and improve the quality of life of patients.At present,there are no studies on tezepelumab in the treatment of severe asthma in China.Therefore,this paper reviews the current research status of tezepelumab in the treatment of severe asthma,in order to provide scientific basis for further clinical application.
作者
杨定权
张焕萍
Yang Dingquan;Zhang Huanping(Department of Respiratory and Critical Care Medicine,Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan 030032,China;Allergy Department,Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan 030032,China)
出处
《实用药物与临床》
CAS
2023年第8期749-755,共7页
Practical Pharmacy and Clinical Remedies
基金
山西白求恩医院人才引进科研启动金项目(2020RC004)
吴阶平医学基金会临床科研专项资助基金(320.6750.2022-02-31)。
